Clinical Trials for Rectal Cancer

A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal adenocarcinoma progressing after 1–2 prior systemic lines, or pancreatic ductal adenocarcinoma progressing after exactly 1 prior line, receive GSK5764227 at cohort-specific dose levels. GSK5764227 is an investigational B7-H3–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06885034

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable metastatic or locally advanced head and neck, lung, gastrointestinal, pancreatic, cervical, endometrial, or urothelial cancer receive STRO-004 alone or with pembrolizumab. STRO-004 is a tissue factor–targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT07227168

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal adenocarcinoma receive GSK5764227 plus bevacizumab, with or without fluorouracil and leucovorin; adults with metastatic castration-resistant prostate adenocarcinoma receive GSK5764227 plus enzalutamide. GSK5764227 is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT07277270

A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic MSS/pMMR colorectal cancer that has progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, or who cannot tolerate standard chemotherapy, receive nadunolimab (an investigational anti-IL1RAP antibody that inhibits IL-1 signaling) plus toripalimab (an anti-PD-1 antibody) every 3 weeks.

ClinicalTrials.gov ID: NCT07281716

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable locally advanced or metastatic KRAS-altered solid tumors, including NSCLC, colorectal cancer, and pancreatic ductal adenocarcinoma, receive oral JAB-23E73 monotherapy. JAB-23E73 is an investigational pan-KRAS inhibitor designed to block KRAS in its active and inactive states; prior KRAS inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT06973564

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced or metastatic RAS-mutant solid tumors are eligible; expansion cohorts include untreated nonsquamous NSCLC and previously treated solid tumors or colorectal cancer. Treatment pairs ivonescimab (PD-1/VEGF-A bispecific antibody) with a RAS(ON) inhibitor—daraxonrasib (multiple RAS variants), elironrasib (KRAS G12C), or zoldonrasib (KRAS G12D)—with selected cohorts adding platinum–pemetrexed, daraxonrasib, or cetuximab.

ClinicalTrials.gov ID: NCT07397338

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, advanced KRAS G12V-mutant solid tumors after progression on or intolerance to standard therapy receive RMC-5127 alone or with daraxonrasib or cetuximab; prior direct RAS-targeted therapy is excluded. RMC-5127 is an investigational inhibitor of active KRAS G12V, daraxonrasib inhibits active RAS across multiple variants, and cetuximab targets EGFR.

ClinicalTrials.gov ID: NCT07349537

A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic esophageal, gastroesophageal junction, gastric, or colorectal adenocarcinoma with measurable disease and ECOG 0–1 receive DISP-10, combining DV-10 adenoviral therapy with BCMA-directed autologous CAR T-cell therapy idecabtagene vicleucel after fludarabine/cyclophosphamide lymphodepletion. The study includes dose escalation and expansion to assess safety and preliminary antitumor activity in GI solid tumors.

ClinicalTrials.gov ID: NCT07544589

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label dose-escalation/expansion study for adults with ECOG 0–1 and advanced unresectable/metastatic MSI and/or dMMR solid tumors, generally after standard therapy. Patients receive oral VVD-133214, a covalent allosteric WRN helicase inhibitor exploiting synthetic lethality in MSI/dMMR tumors, as monotherapy or with pembrolizumab in untreated metastatic CRC or bevacizumab in previously treated metastatic CRC.

ClinicalTrials.gov ID: NCT06004245

A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory, unresectable or metastatic microsatellite-stable colorectal cancer receive investigational pidnarulex, an RNA polymerase I inhibitor that may also stabilize DNA G-quadruplexes, alone or with cemiplimab, an anti-PD-1 antibody. The randomized portion requires liver metastases and MYC amplification or a deleterious FBXW7 mutation.

ClinicalTrials.gov ID: NCT07147231